Effects of inhaled tiotropium plus transdermal tulobuterol versus tiotropium alone on impulse oscillation system (IOS)-assessed measures of peripheral airway resistance and reactance, lung function and quality of life in patients with COPD: A randomized crossover study

Pulmonary Pharmacology and Therapeutics

Volumn 24, Issue 5, 2011, Pages 617-624

  Abe, Tetsuya ^a   Setoguchi, Yasuhiro ^a   Kono, Yuta ^a   Togashi, Yuhki ^a   Sugiyama, Shinya ^a   Tanakadate, Motochika ^a   Soeda, Seiko ^a   Nakai, Michiko ^a   Sugiyama, Norihiro ^a   Fujiwara, Akahito ^a   Yamaguchi, Kouichi ^a   Yamaguchi, Aya ^a   Kurita, Nao ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

COPD; Impulse oscillation system; Tiotropium bromide; Transdermal; Tulobuterol

Indexed keywords

TIOTROPIUM BROMIDE; TULOBUTEROL;

ADULT; AGED; AIRWAY OBSTRUCTION; AIRWAY RESISTANCE; ARTICLE; BEDTIME DOSAGE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DISEASE MARKER; DRUG EFFECT; DRUG ERUPTION; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IMPULSE OSCILLATION SYSTEM; INSPIRATORY CAPACITY; JAPAN; LUNG EXAMINATION; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; MORNING DOSAGE; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; SCORING SYSTEM; SPIROMETRY; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INHALATION; AGED; AGED, 80 AND OVER; AIRWAY RESISTANCE; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; OSCILLOMETRY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; SCOPOLAMINE DERIVATIVES; TERBUTALINE; TRANSDERMAL PATCH; TREATMENT OUTCOME;

EID: 80052408377     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2011.06.002     Document Type: Article

References (44)

1. Agusti A., Soriano J.B. COPD as a systemic disease. COPD 2008, 5:133-138.
2. Decramer M., De Benedetto F., Del Ponte A., Marinari S. Systemic effects of COPD. Respir Med 2005, 99(Suppl. B):S3-S10.
3. Guidelines for the diagnosis and treatment of COPD (Chronic obstructive pulmonary disease) 2004, The Japanese Respiratory Society, Tokyo, Japan. 2nd ed.
4. World Health Organization. Chronic Respiratory Diseases: Burden of Chronic Obstructive Pulmonary Disease.
5. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2009, The Global Initiative for Chronic Obstructive Lung Disease.
6. Fukuchi Y., Nagai A., Seyama K., Nishimura M., Hirata K., Kubo K., et al. Clinical efficacy and safety of transdermal tulobuterol in the treatment of stable COPD: an open-label comparison with inhaled salmeterol. Treat Respir Med 2005, 4:447-455.
7. Ichinose M., Seyama K., Nishimura M., Fukuchi Y., Nagai A., Mishima M., et al. Additive effects of transdermal tulobuterol to inhaled tiotropium in patients with COPD. Respir Med 2010, 104:267-274.
8. Ferrer M., Villasante C., Alonso J., Sobradillo V., Gabriel R., Vilagut G., et al. Interpretation of quality of life scores from the St George's Respiratory Questionnaire. Eur Respir J 2002, 19:405-413.
9. Hogg J.C., Macklem P.T., Thurlbeck W.M. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med 1968, 278:1355-1360.
10. Barnes P.J. Small airways in COPD. N Engl J Med 2004, 350:2635-2637.
11. Hasegawa M., Nasuhara Y., Onodera Y., Makita H., Nagai K., Fuke S., et al. Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173:1309-1315.
12. Hogg J.C., Chu F., Utokaparch S., Woods R., Elliott W.M., Buzatu L., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:2645-2653.
13. Hellinckx J., Cauberghs M., De Boeck K., Demedts M. Evaluation of impulse oscillation system: comparison with forced oscillation technique and body plethysmography. Eur Respir J 2001, 18:564-570.
14. Kanda S., Fujimoto K., Komatsu Y., Yasuo M., Hanaoka M., Kubo K. Evaluation of respiratory impedance in asthma and COPD by an impulse oscillation system. Intern Med 2010, 49:23-30.
15. Pride N.B. Forced oscillation techniques for measuring mechanical properties of the respiratory system. Thorax 1992, 47:317-320.
16. Shiota S., Katoh M., Fujii M., Aoki S., Matsuoka R., Fukuchi Y. Predictive equations and the reliability of the impulse oscillatory system in Japanese adult subjects. Respirology 2005, 10:310-315.
17. Contoli M., Bousquet J., Fabbri L.M., Magnussen H., Rabe K.F., Siafakas N.M., et al. The small airways and distal lung compartment in asthma and COPD: a time for reappraisal. Allergy 2010, 65:141-151.
18. Oostveen E., MacLeod D., Lorino H., Farre R., Hantos Z., Desager K., et al. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur Respir J 2003, 22:1026-1041.
19. Crim C., Celli B., Edwards L.D., Wouters E., Coxson H.O., Tal-Singer R., et al. Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. Respir Med 2011.
20. Takeda T., Oga T., Niimi A., Matsumoto H., Ito I., Yamaguchi M., et al. Relationship between small airway function and health status, dyspnea and disease control in asthma. Respiration 2010, 80:120-126.
21. Houghton C.M., Langley S.J., Singh S.D., Holden J., Monici Preti A.P., Acerbi D., et al. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. Br J Clin Pharmacol 2004, 58:359-366.
22. Ortiz G., Menendez R. The effects of inhaled albuterol and salmeterol in 2- to 5-year-old asthmatic children as measured by impulse oscillometry. J Asthma 2002, 39:531-536.
23. Williamson P.A., Short P.M., Clearie K.L., Vaidyanathan S., Fardon T.C., Howaniec L.J., et al. Paradoxical trough effects of triple therapy with budesonide/formoterol and tiotropium bromide on pulmonary function outcomes in COPD. Chest 2010, 138:595-604.
24. Restrepo R.D., Alvarez M.T., Wittnebel L.D., Sorenson H., Wettstein R., Vines D.L., et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis 2008, 3:371-384.
25. 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995, 152:1107-1136. Standardization of Spirometry.
26. Miller M.R., Crapo R., Hankinson J., Brusasco V., Burgos F., Casaburi R., et al. General considerations for lung function testing. Eur Respir J 2005, 26:153-161.
27. Bourdin A., Paganin F., Prefaut C., Kieseler D., Godard P., Chanez P. Nitrogen washout slope in poorly controlled asthma. Allergy 2006, 61:85-89.
28. Belman M.J., Brooks L.R., Ross D.J., Mohsenifar Z. Variability of breathlessness measurement in patients with chronic obstructive pulmonary disease. Chest 1991, 99:566-571.
29. Simon P.M., Schwartzstein R.M., Weiss J.W., Lahive K., Fencl V., Teghtsoonian M., et al. Distinguishable sensations of breathlessness induced in normal volunteers. Am Rev Respir Dis 1989, 140:1021-1027.
30. Cazzola M., Centanni S., Santus P., Verga M., Mondoni M., di Marco F., et al. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 2004, 98:1214-1221.
31. Hoshino M. Comparison of effectiveness in ciclesonide and fluticasone propionate on small airway function in mild asthma. Allergol Int 2010, 59:59-66.
32. Iikura Y., Uchiyama H., Akimoto K., Ebisawa M., Sakaguchi N., Tsubaki T., et al. Pharmacokinetics and pharmacodynamics of the tulobuterol patch, HN-078, in childhood asthma. Ann Allergy Asthma Immunol 1995, 74:147-151.
33. Kraft M., Cairns C.B., Ellison M.C., Pak J., Irvin C., Wenzel S. Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast. Chest 2006, 130:1726-1732.
34. Cosio M., Ghezzo H., Hogg J.C., Corbin R., Loveland M., Dosman J., et al. The relations between structural changes in small airways and pulmonary-function tests. N Engl J Med 1978, 298:1277-1281.
35. Sutherland E.R., Martin R.J., Bowler R.P., Zhang Y., Rex M.D., Kraft M. Physiologic correlates of distal lung inflammation in asthma. J Allergy Clin Immunol 2004, 113:1046-1050.
36. Borrill Z.L., Houghton C.M., Tal-Singer R., Vessey S.R., Faiferman I., Langley S.J., et al. The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD. Br J Clin Pharmacol 2008, 65:244-252.
37. Akamatsu K., Yamagata T., Takahashi T., Miura K., Maeda S., Yamagata Y., et al. Improvement of pulmonary function and dyspnea by tiotropium in COPD patients using a transdermal beta(2)-agonist. Pulm Pharmacol Ther 2007, 20:701-707.
38. Mead J. Contribution of compliance of airways to frequency-dependent behavior of lungs. J Appl Physiol 1969, 26:670-673.
39. Bouaziz N., Beyaert C., Gauthier R., Monin P., Peslin R., Marchal F. Respiratory system reactance as an indicator of the intrathoracic airway response to methacholine in children. Pediatr Pulmonol 1996, 22:7-13.
40. Van Noord J.A., Clement J., Van de Woestijne K.P., Demedts M. Total respiratory resistance and reactance in patients with asthma, chronic bronchitis, and emphysema. Am Rev Respir Dis 1991, 143:922-927.
41. Barnes P.J. Neural control of human airways in health and disease. Am Rev Respir Dis 1986, 134:1289-1314.
42. Mak J.C., Barnes P.J. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. Am Rev Respir Dis 1990, 141:1559-1568.
43. Enright P.L. Office spirometry: a practical guide to the selection and use of spirometers 1987, Lippincott Williams and Wilkins.
44. Celli B., Decramer M., Kesten S., Liu D., Mehra S., Tashkin D.P. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 180:948-955.